Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsArizona Medicaid Tymlos Coverage Policy | OpenPaye…
    Ask Trek AI about this page
    ModifiedArizona Complete HealthPolicy AZ.CP.PHAR.345

    Clinical Policy: Abaloparatide (Tymlos)

    Customize your policy alerts

    Sign up for Arizona Complete Health Policy AZ.CP.PHAR.345 alerts

    Get alerted when Policy AZ.CP.PHAR.345 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Arizona Medicaid coverage and prior authorization requirements for abaloparatide (Tymlos) for osteoporosis, applying to Arizona Complete Health-Complete Care Plan and Care1st members and providers.

    Policy Summary
    PayerArizona Complete Health
    PolicyClinical Policy: Abaloparatide (Tymlos)
    Policy CodePolicy AZ.CP.PHAR.345
    Change TypeModified
    Effective DateFeb 15, 2021
    Last ReviewFeb 1, 2022
    Next Review DateN/A
    Key ActionSubmit office chart notes, laboratory results, or other clinical information documenting that the member meets all applicable approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    The 2022 annual review updated the definition of very high fracture risk.

    The policy added language specifying that its criteria also apply to Care1st.

    80 mcg/dayMaximum Tymlos dose
    2 yearsMaximum cumulative PTH analog use
    6 monthsInitial approval duration
    12 monthsContinuation approval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Postmenopausal osteoporosisCovered indication

    Coverage Criteria

    Initial therapy - osteoporosis

    Covered for initial therapy when all of the following are met.

    Initial approval criteria

    • Diagnosis and treatment pathway

      • Very high risk for fracture

        • Recent osteoporotic fracture.Within the past 12 months
        • Severely low bone mineral density: Bone mineral density T-score at the hip or spine.≤ -3.0
        • Low bone mineral density with major fracture: Bone mineral density T-score at the hip or spine plus a major osteoporotic fracture of the hip, spine, forearm, wrist, or humerus.≤ -2.5
      • Bisphosphonate treatment pathway: Member completed a 3-year trial of bisphosphonate therapy, with alendronate preferred, at up to maximally indicated doses, unless contraindications or clinically significant adverse effects occurred with both intravenous and oral formulations.3 years

        Prior authorization may be required for bisphosphonate therapy.

    • Age or skeletal maturity: Member is at least 18 years old or has documented closed epiphyses on x-ray.≥ 18 years
    • Forteo history: Member failed Forteo at up to maximally indicated doses, unless Forteo was contraindicated or caused clinically significant adverse effects.

      Prior authorization may be required for Forteo.

    • Lifetime PTH analog exposure: Member has not received 2 years or more of cumulative PTH analog therapy, including Forteo and Tymlos.< 2 years cumulative lifetime use
    • Dose limit: Requested dose does not exceed 80 mcg per day, equivalent to 1 pen every 30 days.80 mcg/day maximum

      Approval duration is 6 months, subject to the lifetime cumulative PTH analog limit.

    Continuation therapy - osteoporosis

    Covered for continuation therapy when all of the following are met.

    Continuation approval criteria

    • Existing coverage or prior approval: Member is currently receiving the medication through a Centene benefit or previously met the initial approval criteria.
    • Positive response: Member is responding positively to therapy.
    • Forteo history: Member has a history of Forteo failure at up to maximally indicated doses, unless Forteo was contraindicated or caused clinically significant adverse effects.

      Prior authorization may be required for Forteo.

    • Lifetime PTH analog exposure: Member has not received 2 years or more of cumulative PTH analog therapy, including Forteo and Tymlos.

    Other diagnoses or indications

    For other diagnoses or indications, coverage requires one of the following.

    • Existing therapy with positive response: Member is currently receiving the medication through a Centene benefit and documentation supports a positive response to therapy.

      Approval duration is the duration of the request or 6 months, whichever is less.

    • Off-label policy review: If the diagnosis is not specifically listed among the indications for which coverage is not authorized, refer to the applicable off-label use policy for the relevant line of business.

      For Arizona Medicaid, refer to AZ.CP.PMN.53.

    Not authorized indications

    Coverage is not authorized for the following indication unless the stated exception applies.

    Non-FDA-approved indications not addressed in this policy are not authorized unless there is sufficient documentation of efficacy and safety under the applicable off-label use policy or evidence of coverage documents.

    For Arizona Medicaid, the applicable off-label use policy is AZ.CP.PMN.53.

    Non-FDA-approved indications not addressed in this policy are not authorized. Coverage may be considered only when sufficient documentation of efficacy and safety supports the use under the applicable Arizona Medicaid off-label use policy (AZ.CP.PMN.53) or applicable evidence of coverage documents.

    Known hypersensitivity to Tymlos is a contraindication. Tymlos also carries a boxed warning regarding the risk of osteosarcoma.

    Clinical Thresholds and Coding Details

    Recent osteoporotic fracture
    Qualifying timingWithin the past 12 months
    Fracture typeRecent osteoporotic fracture
    Coverage pathwayVery high risk for fracture
    Hip or spine BMD T-score
    Measurement siteHip or spine
    Qualifying T-score≤ -3.0
    Clinical pathwayVery high risk for fracture

    Prior Authorization and Provider Actions

    Prior Authorization

    Prior Authorization Documentation Required

    Submit office chart notes, laboratory results, and other clinical documentation demonstrating that the member meets all applicable approval criteria before requesting Tymlos authorization.

    • Include documentation supporting the diagnosis, fracture risk or treatment history, age or closed epiphyses, prior therapy, cumulative PTH analog exposure, and requested dose.
    Step Therapy

    Bisphosphonate Trial Required

    Document a completed 3-year trial of bisphosphonate therapy at up to maximally indicated doses before requesting Tymlos, unless contraindication or clinically significant adverse effects occurred with both intravenous and oral formulations.

    • Alendronate is the preferred bisphosphonate.
    • Prior authorization may be required for bisphosphonates.
    • Document the treatment duration, doses, response, contraindications, or adverse effects.

    Drug and Indication Background

    Abaloparatide (Tymlos) is a human parathyroid hormone-related peptide analog indicated for postmenopausal women with osteoporosis who are at high risk for fracture. Treatment reduces vertebral and nonvertebral fracture risk. High fracture risk includes a history of osteoporotic fracture, multiple fracture risk factors, or failure or intolerance of other osteoporosis therapy. Cumulative use of Tymlos and other PTH analogs is limited to less than 2 years over the member’s lifetime; the product also carries a boxed warning regarding osteosarcoma risk.

    Definitions and Abbreviations

    High risk of fracture
    HistoryHistory of osteoporotic fracture
    Risk profileMultiple risk factors for fracture
    Prior therapyFailure or intolerance to other available osteoporosis therapy
    Policy abbreviations
    BMDBone mineral density
    FDAFood and Drug Administration
    PMOPostmenopausal osteoporosis

    Initial Therapy Criteria

    Initial therapy

    Initial Tymlos therapy for osteoporosis is covered when all of the following are met.

    • Diagnosis and qualifying pathway

      • Very high fracture risk

        • Recent osteoporotic fracture.Within the past 12 months
        • Severely low BMD: BMD T-score at the hip or spine.≤ -3.0
        • BMD with major osteoporotic fracture:

    Continuation Therapy Criteria

    Continuation therapy

    Continuation coverage is covered when all of the following are met.

    • Coverage status: Member is currently receiving the medication through a Centene benefit or previously met the initial approval criteria.
    • Response: Member is responding positively to therapy.
    • Forteo history: Member has a history of Forteo failure at up to maximally indicated doses, unless Forteo was contraindicated or caused clinically significant adverse effects.
    • PTH analog exposure: Member has not received 2 years or more of cumulative PTH analog therapy, including Forteo and Tymlos.

    Required Treatment Sequence

    StepRequirementDuration / dose
    1
    Complete bisphosphonate therapy at up to maximally indicated doses; alendronate is preferred. If contraindicated or clinically significant adverse effects occur with both intravenous and oral formulations, those circumstances may substitute for completion of the trial.
    3 years
    StepRequirementException
    2
    Try Forteo (teriparatide) before Tymlos at up to maximally indicated doses.
    Forteo is not required when it is contraindicated or causes clinically significant adverse effects.

    Dose and Lifetime Quantity Limits

    Tymlos (abaloparatide)
    Daily dose80 mcg per day
    Prefilled pen size3,120 mcg/1.56 mL
    Daily-dose count30 daily doses of 80 mcg per pen
    Tymlos and other PTH analogs
    Maximum cumulative useNo more than 2 years
    Lifetime periodDuring the member's lifetime
    Included therapiesTymlos and other PTH analogs, such as teriparatide (Forteo)
    Policy Summary
    PayerArizona Complete Health
    PolicyClinical Policy: Abaloparatide (Tymlos)
    Policy CodePolicy AZ.CP.PHAR.345
    Change TypeModified
    Effective DateFeb 15, 2021
    Last ReviewFeb 1, 2022
    Next Review DateN/A
    Key ActionSubmit office chart notes, laboratory results, or other clinical information documenting that the member meets all applicable approval criteria.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Coding DetailsPrior Authorization and Provider ActionsDrug and Indication BackgroundDefinitions and AbbreviationsInitial Therapy CriteriaContinuation Therapy CriteriaRequired Treatment SequenceDose and Lifetime Quantity Limits
    < 2 years cumulative lifetime use
  1. Dose increase limit: If the request is for a dose increase, the dose does not exceed 80 mcg per day, equivalent to 1 pen every 30 days.80 mcg/day maximum
  2. BMD T-score with major osteoporotic fracture
    BMD measurement siteHip or spine
    Qualifying T-score≤ -2.5
    Required fracture locationMajor osteoporotic fracture of the hip, spine, forearm, wrist, or humerus
    Bisphosphonate treatment duration
    Required duration3 years
    TreatmentBisphosphonate therapy at up to maximally indicated doses
    Preferred agentAlendronate
    Alternative to completing trialContraindication or clinically significant adverse effects with both IV and oral formulations
    Tymlos maximum dose
    Maximum daily dose80 mcg per day
    Pen utilization limit1 pen every 30 days
    Administration80 mcg subcutaneously once daily
    Cumulative PTH analog exposure
    Lifetime cumulative limitLess than 2 years
    Therapies includedTymlos and other PTH analogs, including Forteo (teriparatide)
    Coverage restrictionThe member must not have received 2 years or more of cumulative PTH analog therapy
    Minimum age
    Minimum age18 years
    Alternative qualificationDocumentation of closed epiphyses on x-ray
    Eligibility pathwayThe member must meet the age requirement or the closed-epiphyses alternative
    Step Therapy

    Forteo Failure or Intolerance Required

    Document failure of Forteo at up to maximally indicated doses before requesting Tymlos, unless Forteo is contraindicated or caused clinically significant adverse effects.

    • Prior authorization may be required for Forteo.
    • Submit the Forteo treatment history, dose, outcome, and any contraindication or intolerance documentation.
    Documentation Required

    Clinical Documentation and Supporting Evidence

    Clinical records must substantiate the diagnosis and medical necessity for Tymlos. Submit records that support the member's fracture risk, prior osteoporosis treatment, and requested regimen.

    • Acceptable records include office chart notes, laboratory results, bone mineral density results, imaging, medication history, and documentation of contraindications or clinically significant adverse effects.
    • For very high fracture risk, document a recent osteoporotic fracture, BMD T-score, and/or qualifying major osteoporotic fracture as applicable.
    Documentation Required

    Initial Therapy Documentation Checklist

    For an initial therapy request, submit documentation showing that all initial approval requirements are met, including postmenopausal osteoporosis and qualifying fracture risk or the required bisphosphonate trial.

    • Document age ≥18 years or closed epiphyses on x-ray.
    • Document Forteo failure, contraindication, or clinically significant intolerance.
    • Document cumulative lifetime PTH analog exposure and the requested dose; the dose may not exceed 80 mcg per day (1 pen every 30 days).
    Documentation Required

    Continuation Therapy Documentation Checklist

    For continuation therapy, document that the member is currently receiving Tymlos through the Centene benefit or previously met initial approval criteria and is responding positively to treatment.

    • Document the history of Forteo failure, contraindication, or clinically significant intolerance.
    • Document cumulative lifetime PTH analog exposure.
    • For a dose increase, confirm the dose does not exceed 80 mcg per day (1 pen every 30 days).

    Unsupported block type: denial_risk

    Denial Risk

    Initial Criteria Not Met

    Initial Tymlos coverage is at risk of denial when the member does not meet every initial approval requirement.

    • No qualifying postmenopausal osteoporosis and fracture-risk pathway is documented.
    • The required 3-year bisphosphonate trial, including both IV and oral formulations when applicable, is not completed or adequately supported.
    • The member is under age 18 without documentation of closed epiphyses.
    • Forteo failure, contraindication, or clinically significant adverse effects are not documented.
    • Cumulative PTH analog use is at least 2 years, or the requested dose exceeds 80 mcg per day (1 pen every 30 days).
    Denial Risk

    Continuation Criteria Not Met

    Continuation Tymlos coverage is at risk of denial when continuation criteria are not met or supporting documentation is incomplete.

    • The member is not currently receiving the medication through the Centene benefit and has not previously met initial approval criteria.
    • The member is not responding positively to therapy.
    • Forteo failure, contraindication, or clinically significant adverse effects are not documented.
    • Cumulative PTH analog use is at least 2 years, or a requested dose increase exceeds 80 mcg per day (1 pen every 30 days).
    Prior Authorization

    Non-FDA Indication Requires Exception Documentation

    Coverage is not authorized for non-FDA-approved indications that are not addressed by this policy unless the request includes sufficient evidence of efficacy and safety under the applicable off-label-use policy or evidence-of-coverage documents.

    • For Arizona Medicaid, submit supporting evidence consistent with off-label use policy AZ.CP.PMN.53 when applicable.
    • Include the diagnosis, clinical rationale, and evidence supporting efficacy and safety.

    Unsupported block type: denial_risk

    PTH
    Parathyroid hormone
    BMD T-score at the hip or spine plus a major osteoporotic fracture of the hip, spine, forearm, wrist, or humerus.
    ≤ -2.5
  3. Bisphosphonate pathway: Member completed a 3-year trial of bisphosphonate therapy, with alendronate preferred, at up to maximally indicated doses, unless contraindications or clinically significant adverse effects occurred with both intravenous and oral formulations.3 years
  4. Age or skeletal maturity: Member is at least 18 years old or has documented closed epiphyses on x-ray.≥ 18 years
  5. Forteo history: Member failed Forteo at up to maximally indicated doses, unless Forteo was contraindicated or caused clinically significant adverse effects.
  6. Cumulative PTH analog exposure: Member has not received 2 years or more of cumulative PTH analog therapy, including Forteo and Tymlos.< 2 years lifetime
  7. Dose limit: Requested dose does not exceed 80 mcg per day or 1 pen every 30 days.80 mcg/day maximum
  8. < 2 years lifetime
  9. Dose increase: If the request is for a dose increase, the dose does not exceed 80 mcg per day or 1 pen every 30 days.80 mcg/day maximum